SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Carcinoma Intervention:   Drug: SHR-1701 Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials